Information Provided By: 
Fly News Breaks for April 2, 2015
OVAS
Apr 2, 2015 | 08:32 EDT
After OvaScience fell over 40% over the last week, Oppenheimer says that the decline is primarily due to a misunderstanding of the data recently presented by the company. The firm says there has been confusion about the pregnancy rate achieved with AUGMENT, and Oppenheimer says that the pregnancy rate is favorable. Oppenheimer believes that there were other favorable data points for AUGMENT, and it keeps a $60 price target and Outperform rating on the shares.
News For OVAS From the Last 2 Days
There are no results for your query OVAS
